目的 探索消癌平注射液聯(lián)合PP化療方案治療中晚期肺腺癌患者的臨床療效。方法 選取淮南東方醫(yī)院集團(tuán)總醫(yī)院于2021年1月—2023年12月收治的78例肺腺癌（LUAD）患者，按隨機(jī)原則分為對(duì)照組與治療組，每組各39例。對(duì)照組患者靜脈滴注注射用培美曲塞二鈉，500 mg/m²，靜脈滴注1 h，順鉑注射液75 mg/m²，靜脈滴注3 h。治療組患者在對(duì)照組基礎(chǔ)上靜脈滴注消癌平注射液，60 mL/次，用5%葡萄糖注射液稀釋至500 mL后滴注，連續(xù)滴注7 d，1次/d。21 d為1個(gè)周期，共治療6個(gè)周期。觀(guān)察兩組患者臨床療效，比較治療前后兩組患者Piper疲乏修訂量表，QLQ-C30生活質(zhì)量評(píng)分，腫瘤標(biāo)志物癌胚抗原（CEA）和細(xì)胞角蛋白19片段（CYFRA21-1）水平，及不良反應(yīng)情況。結(jié)果 治療組在客觀(guān)緩解率上優(yōu)于對(duì)照組（66.67% vs 43.59%，P＜0.05）。治療3個(gè)周期后，治療組患者Piper疲乏修訂量表評(píng)分較治療前顯著下降（P＜0.05）。治療6個(gè)周期后，兩組患者較治療前評(píng)分顯著下降（P＜0.01），治療組患者癌因性疲乏評(píng)分顯著低于對(duì)照組（P＜0.05），治療6個(gè)周期后，治療組患者生活質(zhì)量評(píng)分高于治療前（P＜0.05），且高于對(duì)照組（P＜0.05）。治療后，兩組患者腫瘤標(biāo)志物CEA、CYFRA21-1均顯著下降（P＜0.05、0.01），且治療組CEA、CYFRA21-1均低于對(duì)照組（P＜0.05）。治療組不良反應(yīng)發(fā)生率顯著低于對(duì)照組（P＜0.05）。結(jié)論 消癌平注射液聯(lián)合PP化療治療中晚期肺腺癌患者具有顯著協(xié)同增效減毒效果，在改善患者癌因性疲乏方面效果顯著。

Objective To explore the clinical efficacy of Xiaoaiping Injection combined with PP chemotherapy in treatment of advanced lung adenocarcinoma. Methods Patients (78 cases) with advanced lung adenocarcinoma in General Hospital of Huainan Oriental Hospital Group from January 2021 to December 2023 were divided into control and treatment group according to the principle of randomization, and each group had 39 cases. Patients in the control group were iv administered with Pemetrexed Disodium for injection for 1 h, 500 mg/m², and they were iv administered with Cisplatin Injection for 3 h, 75 mg/m², 21 d was a cycle, and the total of 6 cycles of treatment were performed. Patients in the treatment group were iv administered with Xiaoaiping Injection on the basis of the control group for 7 d, 60 mL/time, added into 500 mL 5% glucose injection, once daily. After treatment, the clinical evaluations were evaluated, and the Piper Fatigue Scale-Revised score, QLQ-C30 quality of life, tumor markers CEA and CYFRA21-1, and adverse reaction in two groups before and after treatment were compared. Results The objective remission rate of the treatment group was better than that of the control group ( 66.67 % vs 43.59 %, P < 0.05 ). After 3 cycles of treatment, the scores of Piper Fatigue Scale-Revised in the treatment group were significantly decreased compared with those before treatment (P < 0.05). After 6 cycles of treatment, the scores of patients in two groups were significantly decreased compared with those before treatment (P < 0.01). The scores of cancer-related fatigue in the treatment group were significantly lower than those in the control group (P < 0.05). After 5 cycles of treatment, the scores of patients in the treatment group were higher than those before treatment (P < 0.05) and higher than those in the control group (P < 0.05). After treatment, the tumor markers CEA and CYFRA21-1 were significantly decreased in two groups (P < 0.05, 0.01), and CEA and CYFRA21-1 in the treatment group were lower than those in the control group (P < 0.05). The incidence of adverse reactions in the treatment group was significantly lower than that in the control group (P < 0.05). Conclusion Xiaoaiping Injection combined with PP chemotherapy has a significant synergistic effect of enhancing efficacy and reducing toxicity in the treatment of patients with advanced lung adenocarcinoma, and is effective in improving cancer-related fatigue in patients.

R979.1